novavax vaccine - Search News

Order byBest matchMost fresh

Novavax scores narrower Covid vaccine approval

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's Covid-19 vaccine after more than a month of delay b

· 2d · on MSN

Infectious Disease Advisor · 1d

FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid

WebMD · 2d

FDA Approves Novavax COVID Vaccine With Restricted Use

New Trump vaccine policy limits access to COVID shots

The Trump administration said Tuesday it will limit approval for seasonal COVID-19 shots to seniors and others at high risk pending more data on everyone else — raising questions about whether some p...

· 1d

· 10h

FDA panel recommends keeping COVID shots targeted to same strain as last year

· 1d

FDA limits access to COVID-19 vaccine to older adults and other high-risk groups – a public health expert explains the new rules

FDA plans to limit COVID vaccine to only high-risk people. Who would still be eligible?

Public trust in vaccination has declined, potentially impacting other vital immunization programs.

· 1d

· 15h

FDA panel debates COVID vaccine recipe as questions swirl about fall shots

· 14h

US FDA Advisers to Weigh Composition of COVID Vaccines for 2025-2026

STAT4h

FDA gives Covid vaccine manufacturers instructions for next fall’s shot

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to update their vaccines.

4don MSN

FDA approves Novavax's COVID-19 vaccine with limitations

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

New Trump vaccine policy might limit access to your future COVID shots: 10 points

The US Food and Drug Administration changes Covid-19 vaccine approval process. Access to seasonal boosters is restricted for healthy individuals under 65. This decision contrasts with previous recommendations for annual shots for all.

JPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive News

JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This comes after the Food and Drug Administration (FDA) approved the company’s COVID-19 vaccine,

Explore more

Covid

Food and Drug Administration